# UNITEDHEALTHCARE FORMULARY ANALYSIS: 2025 → 2026

Generated: 2025-12-23 20:05:44
Mode: txt_extraction
Source: uhc_2025.pdf (93 pages)
        uhc_2026.pdf (80 pages)

--------------------------------------------------------------------------------

# UnitedHealthcare Formulary Comparison: 2025 vs 2026

## Executive Summary

This analysis compares the September 2025 and January 2026 UnitedHealthcare Prescription Drug Lists. Key themes include **generic substitution expansion**, **tier restructuring for cost optimization**, **new specialty drug additions**, and **restriction policy changes**.

---

## 1. Drug Additions (New in 2026)

### Brand-Name Additions

| Drug Name     | Therapeutic Class        | Tier   | Restrictions   | Notes                             |
| ------------- | ------------------------ | ------ | -------------- | --------------------------------- |
| **JOURNAVX**  | Analgesics (Pain)        | Tier 4 | QL             | New non-opioid pain medication    |
| **RALDESY**   | Antidepressants          | Tier 4 | PA             | New antidepressant option         |
| **IMKELDI**   | Antineoplastics (Cancer) | Tier 4 | PA, QL, SP     | New oncology agent                |
| **SCEMBLIX**  | Antineoplastics (Cancer) | Tier 4 | PA, QL, SP     | CML treatment                     |
| **XALKORI**   | Antineoplastics (Cancer) | Tier 4 | PA, QL, SP     | ALK-positive NSCLC                |
| **BESREMI**   | Antineoplastics (Cancer) | Tier 4 | PA, QL, SP     | Polycythemia vera                 |
| **RYDAPT**    | Antineoplastics (Cancer) | Tier 2 | PA, QL, SP     | AML/mastocytosis                  |
| **MAVENCLAD** | Multiple Sclerosis       | Tier 3 | PA, ST, QL, SP | Also listed under antineoplastics |

### Generic Additions

| Drug Name                                    | Therapeutic Class | Tier   | Notes                      |
| -------------------------------------------- | ----------------- | ------ | -------------------------- |
| **rivaroxaban** (generic Xarelto)            | Anticoagulants    | Tier 2 | New generic availability   |
| **fidaxomicin** (generic Dificid)            | Antibacterials    | Tier 3 | C. diff treatment          |
| **ticagrelor** (generic Brilinta)            | Antiplatelets     | Tier 3 | Antiplatelet therapy       |
| **nilotinib hcl** (generic Tasigna)          | Antineoplastics   | Tier 2 | CML treatment              |
| **eslicarbazepine acetate** (generic Aptiom) | Anticonvulsants   | Tier 3 | Seizure control            |
| **perampanel** (generic Fycompa)             | Anticonvulsants   | Tier 2 | Seizure control            |
| **rivastigmine tartrate**                    | Antidementia      | Tier 1 | Moved to Tier 1 as generic |

---

## 2. Drug Removals (No Longer Listed in 2026)

### Removed from Formulary

| Drug Name                          | 2025 Tier | Therapeutic Class          | Likely Reason                            |
| ---------------------------------- | --------- | -------------------------- | ---------------------------------------- |
| **KLOXXADO**                       | Tier 4    | Substance Abuse (Naloxone) | Consolidation to other naloxone products |
| **REXTOVY**                        | Tier 1    | Substance Abuse            | Formulary consolidation                  |
| **acamprosate calcium**            | Tier 1    | Substance Abuse            | Possible removal or reclassification     |
| **NICODERM CQ**                    | Tier 2    | Smoking Cessation          | May be OTC-only now                      |
| **NICOTROL**                       | Tier 2    | Smoking Cessation          | May be OTC-only now                      |
| **glydo**                          | Tier 1    | Analgesics (Lidocaine)     | Product consolidation                    |
| **lidocaine hcl urethral/mucosal** | Tier 1    | Analgesics                 | Removed from coverage                    |
| **lidocaine-prilocaine**           | Tier 1    | Analgesics                 | Removed from coverage                    |
| **FIRVANQ**                        | Tier 2    | Antibacterials             | Vancomycin formulation removed           |
| **XACIATO**                        | Tier 2    | Antibacterials             | Clindamycin formulation removed          |
| **granisetron hcl oral**           | Tier 1    | Antiemetics                | Possible generic consolidation           |
| **NUPLAZID**                       | Tier 4    | Antiparkinson              | Parkinson's psychosis drug removed       |
| **KYNMOBI**                        | Tier 4    | Antiparkinson              | Apomorphine sublingual removed           |
| **galantamine hydrobromide er**    | Tier 1    | Antidementia               | Removed from formulary                   |

---

## 3. Tier Changes

### Drugs Moving to LOWER Tiers (Cost Decrease)

| Drug Name                 | 2025 Tier             | 2026 Tier        | Therapeutic Class | Impact                     |
| ------------------------- | --------------------- | ---------------- | ----------------- | -------------------------- |
| **rivastigmine tartrate** | Tier 3                | Tier 1           | Antidementia      | Significant cost reduction |
| **celecoxib**             | Tier 1 (brand Tier 2) | Tier 2 (generic) | NSAIDs            | Generic now preferred      |
| **KISQALI**               | Tier 4                | Tier 2           | Antineoplastics   | Major cost improvement     |
| **perampanel**            | Tier 2 (brand)        | Tier 2 (generic) | Anticonvulsants   | Generic availability       |
| **lamotrigine er**        | Tier 3                | Tier 2           | Anticonvulsants   | Improved access            |
| **dronabinol**            | Tier 1                | Tier 3           | Antiemetics       | Tier increase (see below)  |

### Drugs Moving to HIGHER Tiers (Cost Increase)

| Drug Name                   | 2025 Tier | 2026 Tier | Therapeutic Class | Impact                    |
| --------------------------- | --------- | --------- | ----------------- | ------------------------- |
| **dronabinol**              | Tier 1    | Tier 3    | Antiemetics       | Significant cost increase |
| **fosfomycin tromethamine** | Tier 1    | Tier 3    | Antibacterials    | Cost increase             |
| **tetracycline hcl**        | Tier 1    | Tier 3    | Antibacterials    | Cost increase             |
| **tinidazole**              | Tier 1    | Tier 3    | Antibacterials    | Cost increase             |
| **GAVRETO**                 | Tier 2    | Tier 4    | Antineoplastics   | Cost increase             |
| **IBRANCE**                 | Tier 2    | Tier 4    | Antineoplastics   | Cost increase, added ST   |
| **INBRIJA**                 | Tier 2    | Tier 3    | Antiparkinson     | Cost increase             |
| **CREXONT**                 | Tier 2    | Tier 4    | Antiparkinson     | Cost increase             |
| **eletriptan hydrobromide** | Tier 1    | Tier 2    | Antimigraine      | Cost increase             |
| **frovatriptan succinate**  | Tier 1    | Tier 3    | Antimigraine      | Significant cost increase |
| **CAPLYTA**                 | Tier 2    | Tier 4    | Antipsychotics    | Cost increase             |
| **colchicine**              | Tier 1    | Tier 2    | Antigout          | Cost increase             |
| **febuxostat**              | Tier 1    | Tier 3    | Antigout          | Cost increase             |
| **econazole nitrate**       | Tier 1    | Tier 2    | Antifungals       | Cost increase             |
| **terbinafine hcl**         | Tier 1    | Tier 2    | Antifungals       | Cost increase             |
| **terconazole**             | Tier 1    | Tier 2    | Antifungals       | Cost increase             |

---

## 4. Restriction Changes

### New Prior Authorization (PA) Requirements

| Drug Name            | 2025 Status | 2026 Status | Notes                     |
| -------------------- | ----------- | ----------- | ------------------------- |
| **primidone 125 mg** | No PA       | PA          | New restriction           |
| **MYSOLINE**         | No PA       | PA          | Brand now requires PA     |
| **CAPLYTA**          | No PA       | PA, ST, QL  | Multiple new restrictions |
| **IBRANCE tablet**   | PA, QL      | PA, ST, QL  | Added Step Therapy        |

### New Step Therapy (ST) Requirements

| Drug Name          | 2025 Status | 2026 Status    | Therapeutic Class              |
| ------------------ | ----------- | -------------- | ------------------------------ |
| **IBRANCE tablet** | PA, QL, SP  | PA, ST, QL, SP | Antineoplastics                |
| **CAPLYTA**        | None        | PA, ST, QL     | Antipsychotics/Antidepressants |
| **nilotinib hcl**  | N/A (new)   | PA, ST, QL, SP | Antineoplastics                |

### Removed Restrictions

| Drug Name                        | 2025 Restrictions     | 2026 Restrictions | Change                        |
| -------------------------------- | --------------------- | ----------------- | ----------------------------- |
| **buprenorphine hcl sublingual** | QL                    | QL                | No change                     |
| **fentanyl transdermal**         | Tier 1 (some), PA, QL | Tier 2, PA, QL    | Simplified but tier increased |

---

## 5. Biosimilar and Generic Substitution Changes

### New Generic Availability (Brand → Generic Preferred)

| Brand Name   | Generic Name            | 2025 Status    | 2026 Status              |
| ------------ | ----------------------- | -------------- | ------------------------ |
| **Xarelto**  | rivaroxaban             | Brand Tier 2   | Generic Tier 2 available |
| **Brilinta** | ticagrelor              | Brand Tier 2   | Generic Tier 3           |
| **Dificid**  | fidaxomicin             | Brand Tier 2   | Generic Tier 3           |
| **Tasigna**  | nilotinib hcl           | Brand excluded | Generic Tier 2           |
| **Aptiom**   | eslicarbazepine acetate | Brand Tier 3   | Generic Tier 3           |
| **Fycompa**  | perampanel              | Brand Tier 2   | Generic Tier 2           |

### Brand Exclusions Due to Generic Availability

| Brand Name   | Therapeutic Class | 2026 Status                               |
| ------------ | ----------------- | ----------------------------------------- |
| **BRILINTA** | Antiplatelets     | Excluded (generic ticagrelor available)   |
| **COLCRYS**  | Antigout          | Excluded (generic colchicine available)   |
| **EXELON**   | Antidementia      | Excluded (generic rivastigmine available) |

---

## 6. Therapeutic Class Coverage Changes

### Analgesics (Pain)
- **JOURNAVX** added as new non-opioid option (Tier 4)
- **BUTRANS** moved from Tier 2 to Excluded
- **DILAUDID tablet** moved to Excluded
- Lidocaine products consolidated; some removed

### Anticoagulants
- **rivaroxaban generic** added at Tier 2
- Simplified tier structure for DOACs

### Anticonvulsants
- Multiple generics added (perampanel, eslicarbazepine)
- **LYRICA** added to Tier 4 (was not explicitly listed in 2025)
- **lamotrigine er** improved to Tier 2

### Antineoplastics (Cancer)
- **5 new agents** added (IMKELDI, SCEMBLIX, XALKORI, BESREMI, RYDAPT)
- **KISQALI** significantly improved (Tier 4 → Tier 2)
- **IBRANCE** worsened (Tier 2 → Tier 4, added ST)
- **GAVRETO** worsened (Tier 2 → Tier 4)
- **nilotinib generic** added as Tasigna alternative

### Antiplatelets
- **BRILINTA** moved to Excluded
- **ticagrelor generic** added at Tier 3
- Net cost increase for patients on this therapy

### Antipsychotics
- **CAPLYTA** moved from Tier 2 to Tier 4 with new PA, ST, QL
- **GEODON** moved to Excluded
- **INVEGA** moved to Excluded

### Multiple Sclerosis
- **MAVENCLAD** added (Tier 3)
- **dimethyl fumarate** and **fingolimod** generics at Tier 1
- Improved generic access for MS patients

---

## 7. Key Formulary Policy Changes

| Policy Area            | 2025              | 2026            | Impact                          |
| ---------------------- | ----------------- | --------------- | ------------------------------- |
| **Effective Date**     | September 1, 2025 | January 1, 2026 | Standard annual update          |
| **Tier 4 Description** | "Variable"        | "Specialty"     | Clarified specialty designation |
| **Generic Preference** | Strong            | Stronger        | More generics at Tier 1         |

---

## 8. Cost Impact Summary

### Therapeutic Areas with IMPROVED Access (Lower Cost)
1. **Multiple Sclerosis** - Generic fingolimod and dimethyl fumarate at Tier 1
2. **Antidementia** - Rivastigmine moved to Tier 1
3. **Anticonvulsants** - More generics, lamotrigine ER improved
4. **Cancer (select)** - KISQALI significantly improved

### Therapeutic Areas with REDUCED Access (Higher Cost)
1. **Antimigraine** - Triptans moved to higher tiers
2. **Antigout** - Colchicine and febuxostat tier increases
3. **Antifungals** - Multiple tier increases
4. **Antiplatelets** - Brilinta excluded, generic at higher tier
5. **Cancer (select)** - IBRANCE, GAVRETO worsened

---

## 9. Recommendations for Plan Sponsors

### High-Priority Actions
1. **Communicate antiplatelet changes** - Members on Brilinta need transition to ticagrelor generic
2. **Review oncology authorizations** - IBRANCE now requires Step Therapy
3. **Update migraine protocols** - Triptan tier changes affect cost sharing
4. **MS patient outreach** - Highlight new Tier 1 generic options

### Cost Optimization Opportunities
1. Promote generic rivaroxaban over brand Xarelto
2. Transition Exelon patients to generic rivastigmine
3. Utilize Tier 1 MS generics (fingolimod, dimethyl fumarate)

---

## 10. Summary Statistics

| Metric                        | Count |
| ----------------------------- | ----- |
| **New Drug Additions**        | ~15   |
| **Drug Removals**             | ~15   |
| **Tier Decreases (Improved)** | ~8    |
| **Tier Increases (Worsened)** | ~18   |
| **New PA Requirements**       | ~5    |
| **New ST Requirements**       | ~4    |
| **New Generic Alternatives**  | ~6    |